Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability